Theranostics: A holistic and revolutionized regime in cardiovascular medicine





Eiji Matsuura, PhD

Professor

Okayama University Neutron Therapy Research Center, Collaborative Research Center & Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, *Okayama, Japan E-mail: eijimatu@md.okayama-u.ac.jp*

Location and Feature of Okayama... Sunny, Mild Climate, Historical city & Nice food



Research Collaborations

岡山大学

OKAYAMA UNIV

UNIVERSITAS INDONESIA

Veritas, Probitas, Iustitia

- Memorandum of Understanding (MoU)
- Research collaborations
- Co-supervision of postgraduates
- ✓ Joint paper publications

PUSAT JANTUNG

WE CARE FOR YOUR HEART

SWIN

SWINBURNE UNIVERSITY OF TECHNOLOGY



Dr. Alan Yean Yip Fong Sarawak General Hospital



Dr. Hwang Siaw San Swinburne Sarawak



Prof. Mrinal Bhave Swinburne Melbourne

Prof. Yosry Morsi

Swinburne Melbourne

Dr. Rani Sauriasari Universitas Indonesia


Prof. Eiji Matsuura

Okayama University


Adjun c t Professor

SUT at Melbourne Adjun c t Professor

SUTSUT at Sarawak



Concept of Antibody Labeling with ⁶⁴Cu/⁸⁹Zr








Harnessing Disease-specific Autoantibody And Its Variant in Theranostics Of Disease

The term "Theranostics", is an innovative concept of medical modality featuring a portmanteau of therapeutic and diagnostic systems, was coined in 2002 and has since undergone progressive development into current preclinical stages.



Antiphospholipid syndrome (APS) (Autoimmune-mediated atherosclerosis)

Disease concepts


- Thrombotic autoimmune disease
- Caused by a set of autoantibodies, so called <u>"antiphospholipid antibodies (aPL)"</u>

Clinical criteria

- <u>Arterial</u> and/or venous thrombosis
- Pregnancy morbidities

Autoantibodies

- Anti-cardiolipin antibodies $\rightarrow X$
- <u>Anti-β2-glycoprotein I (β2GPI) antibodies</u>
- Lupus anticoagulants \rightarrow ???



Stroke








β2-Glycoprotein I (β2GPI)

(A major target antigen of antiphospholipid antibodies)





III IV V IV V V IV <td

Reprinted from THE LANCET, July 21, 1990, pp. 177-178

Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease

SIR,—At the 4th International Symposium on Antiphospholipid Antibodies, held in Italy in April, 1990, we reported that anticardiolipin antibodies (ACA), obtained from the sera of autoimmune patients, reacted with a complex of negatively charged phospholipids and cofactor(s) derived from normal human sera.¹ We can confirm that the anticardiolipin cofactor(s) we reported is identical to Dr Galli and colleagues' "ACA-cofactor" (June 30, p 1544).

We purified a cofactor by cellulose column chromatography and affinity chromatography using columns conjugated with protein A




Fig 1—Analytical electrophoresis on SDS-polyacrylamide gel of human anticardiolipin cofactor(s).

LMW = low-molecular-weight markers.

$$\label{eq:Fr.1N} \begin{split} Fr.1N = cofactor(s) - enriched fraction obtained by column chromatography (eluted with 14 mmol/l phosphate buffer, pH7-4) followed by affinity chromatography on columns conjugated with protein A and murine monoclonal anti-human IgG. \end{split}$$

F-1 = fraction adsorbed on liposomes composed of cardiolipin.

F-2 = fraction adsorbed on liposomes composed of cardiolipin and dipalmitoylphosphatidylcholine (DPPC) (20:80, mol %).


F-3=fraction adsorbed on liposomes composed of dipalmitoylphosphatidylethanolamine (DPPE) and DPPC (20:80, mol %). No bands detected.

Lancet 1990

Anti-cardiolipin cofactor (mw 50 kDa) *Lancet 1990, Lancet 1991, J Immunol 1992* cDNA cloning of β2GPI's cDNA and its protein primary structure *Int Immunol 1991*

X-ray electron spectroscopy (XPS) provided an idea that the epitopes are cryptic J Exp Med 1994


The epitopes characterized with recombinant mutants expressed in baculovirus expression system *Clin Exp Immunol 1993, Blood 1996*



Eiji Matsuura, PhD. Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences

10

Regulatory function of β2GPI in haemostasis




Eiji Matsuura, PhD. Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences


The AtherOx[®] Technology (for *in vitro* diagnosis & *in vivo* imaging)

AtherOx: Complexation of oxidized low-density lipoprotein (oxLDL) and β_2 -glycoprotein I (β_2 GPI).

Proprietary atherosclerosis biomarker (US Registered trademark)




Unique feature: unlike native LDL, oxLDL binds β_2 GPI (oxLDL/ β_2 GPI complexes) β_2 GPI bridges oxidative stress and immunology to atherothrombotic CVD



A diagnostic marker of vascular inflammation AtherOx[®] and IgG/IgM Anti-AtherOx[®]

Assay kit for oxLDL/ β 2GPI complex and IgG/IgM anti-oxLDL/ β 2GPI Abs







Related assay kits (now developing..) Human CRP/oxLDL/β2GPI immune complex Mouse SAP/oxLDL/β2GPI complex

Prospected number of target-disease population and market size of the PET imaging for LDL• β 2GPI complexes (AtherOx [®])


(By Japanese DGAO-Study)



Specificity of 3H3 scFv (anti-oxLDL/β2GPI) In vitro study with aorta of the WHHL rabbits




Immunostaining with



Summary of PET imaging of atherosclerotic plaques in the WHHL rabbits

CT (angiography) PET Aortic arch imaging Gross Sudan IV Autoradiofeature (lipids) graphy CT (angio) PET Cont AT Cont AT Cont AT CT (angio) Abdominal Aorta (Branch to renal artery) WHHL Control

Targeted therapy and diagnosis of atherosclerotic disease





ABOUT US

Cardiovascular Solutions and Innovations, LLC (CSI) is Okayama University's first bio-venture locates outside Japan. With offices in South Bend, Indiana (USA), CSI offers consulting services to global research community. CSI helps usher translational research (TR) in cardiovascular medicine from the bench to the bedside.

MISSION

Building on years of experience in the development and commercialization of medical devices, CSI works diligently to assist its partner in achieving their project goal in an expeditious manner.

Contact



Kirk Guyer (USA) Managing Director © +1-574-532-9957 ⊠ kguyer@iusb.edu

Eiji Matsuura (Japan) Managing Director

ℓ +81-86-235-6529
∞ eijimatu@md.okayama-u.ac.jp

Bench-to-Bedside...

Consulting Services

Clinical and Translational Research Platform

CSI assists laboratory scientists, researchers, and clinicians to coordinate their efforts toward a common goal. As a bioventure of Okayama University, CSI's access to state of the art facilities and equipment provides the platforms necessary to facilitate the innovation and advancement of medical devices.

Medical Device Licensing

With a proven track record in medical device registrations, CSI assists its partners to prepare, submit, and secure regulatory clearance for their medical devices.



In-Vitro Diagnostics

lgG scFv (150 kDa) (25 kDa) Antibody Humanization

In-Vivo PET Imaging